NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Spesolimab for treating generalised pustular psoriasis flares ID3963

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|-----|---|
| No | |
| | |
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the Committee? |
| N/A | |
| | |
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
| N/A | |
| | |
| 4. | Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made? |
| N/A | |
| | Accepted Biocheckers Co. |

Approved by Associate Director (name): Emily Crowe

Date: 17/06/2024

Health Technology Evaluation: Scoping

Equality impact assessment for the Health Technology Evaluation of spesolimab for treating

generalised pustular psoriasis flares

Issue date: June 2024 1 of 1